Europe Pharmaceutical Excipients Market is expected to reach US$ 4,191.0 Million by 2034

According to The Insight Partners' research, the Europe Pharmaceutical Excipients Market was valued at US$ 2,359.7 Million in 2025 and is expected to reach US$ 4,191.0 Million by 2034, registering a CAGR of 6.7% from 2026 to 2034.

Shift toward patient-centric and continuous manufacturing and rising adoption of biologics and novel delivery systems are among the critical factors attributed to drive the Europe pharmaceutical excipients market.

The pharmaceutical excipients market is evolving with a pronounced shift toward patient-centric and continuous manufacturing paradigms, prioritizing personalized formulations and streamlined production to improve adherence, efficacy, and efficiency. Patient-centric approaches focus on tailoring excipient selections to individual needs, such as ease of swallowing or reduced bitterness, particularly for vulnerable populations such as the elderly and pediatrics patients. A review of solid oral dosage form (SODF) attributes highlights preferences for smaller tablet sizes (under 12 mm diameter) and film-coated surfaces to minimize choking risks, with studies showing up to 70% of patients favoring mini-tablets over traditional ones for better compliance in chronic conditions. Compounding pharmacies exemplify this by customizing excipients such as flavor-masking agents (e.g., cyclodextrins) in liquid formulations for pediatric oncology drugs, addressing biopharmaceutical challenges in elderly patients where demographic shifts demand age-specific viscosity adjustments in suspensions.

Precision medicine integrates excipients in extemporaneous preparations; for example, tablet splitting or liquid dispensing with polymers such as hypromellose ensures dose accuracy for 30-50% of therapies requiring personalization, reducing errors in low-dose APIs. Continuous manufacturing enhances excipient integration by enabling real-time quality control, contrasting batch processes' variability. Additionally, continuous methods achieve blend uniformity with relative standard deviation (RSD) of 2-6% for binary and ternary mixtures (e.g., lactose, microcrystalline cellulose [MCC], and paracetamol at 2-30% API), compared to batch blending's up to 68% RSD due to segregation from density mismatches (0.34-0.72 g/cm³). This robustness persists across particle sizes (38-180 μm) and morphologies, with residence times of 30-60 seconds minimizing deagglomeration issues; for ternary blends at 1:1 ratios, continuous RSD remains under 8%, independent of excipient flowability. Examples include twin-screw wet granulation (TSWG) for quetiapine fumarate immediate-release tablets, optimizing excipient ratios (e.g., 50% MCC, 20% lactose) to yield consistent granule sizes (150-500 μm) and dissolution profiles (>80% in 30 minutes), outperforming batch granulation's 10-20% variability. Hot-melt extrusion (HME) for low-dose carvedilol self-emulsifying systems (2% API) demonstrates continuous superiority, with HME yielding uniform content (RSD <3%) versus spray-drying's higher fluctuations from excipient hygroscopicity. These trends align with FDA guidance on process analytical technology (PAT), where sensor networks monitor excipient moisture (2-5%) in real-time, reducing defects by 15-25% in pilot-scale lines. By combining patient-centric excipient design, such as natural sweeteners in orodispersible films, with continuous platforms such as direct compression (achieving 95% yield vs. batch's 85%), manufacturers address shortages impacting 20-30% of patients financially and clinically. This synergy not only boosts bioavailability but also supports sustainable scaling, with over 50% of new facilities adopting continuous lines for excipient-heavy generics.

On the contrary, stringent and complex regulatory frameworks hamper the growth of the Europe pharmaceutical excipients market.

Europe Pharmaceutical Excipients Market Segmentation Analysis:

• By Type, the Europe Pharmaceutical Excipients Market is segmented into Bioresorbable Polymers and Lipids and Liposome Based Formulation, Oleochemicals, Sugars, Cellulose, Starches, Petrochemicals, Plant Proteins Polyols and Cyclodextrins, Inorganic Chemicals, and Others. The Cellulose segment is projected to expand at a CAGR of 6.5% during 2026 - 2034.
• By Oleochemicals For Type, the Europe Pharmaceutical Excipients Market is segmented into Fatty Alcohols, Metal Stearates, Glycerin, and Other Oleochemicals. The Fatty Alcohols segment is projected to expand at a CAGR of 7.2% during 2026 - 2034.
• By Sugars For Type, the Europe Pharmaceutical Excipients Market is segmented into Actual Sugars, Sugar Alcohols, and Artificial Sweeteners. The Actual Sugars segment is projected to expand at a CAGR of 5.8% during 2026 - 2034.
• By Cellulose For Type, the Europe Pharmaceutical Excipients Market is segmented into Microcrystalline Cellulose, Cellulose Ethers, and Carboxymethylcellulose and Croscarmellose Sodium. The Microcrystalline Cellulose segment is projected to expand at a CAGR of 6.6% during 2026 - 2034.
• By Starches For Type, the Europe Pharmaceutical Excipients Market is segmented into Modified Starches, Dried Starch, and Converted Starch and Pregelatinized Starch. The Modified Starches segment is projected to expand at a CAGR of 5.0% during 2026 - 2034.
• By Petrochemicals For Type, the Europe Pharmaceutical Excipients Market is segmented into Glycols, Povidones, Mineral Hydrocarbons, and Other Petrochemicals. The Glycols segment is projected to expand at a CAGR of 6.5% during 2026 - 2034.
• By Inorganic Chemicals For Type, the Europe Pharmaceutical Excipients Market is segmented into Magnesium and Calcium Carbonate, Calcium and Aluminum Phosphate, Silicon Dioxide, Titanium Dioxide, and Other Inorganic Chemicals. The Calcium and Aluminum Phosphate segment is projected to expand at a CAGR of 8.1% during 2026 - 2034.
• By Clinical Indication, the Europe Pharmaceutical Excipients Market is segmented into Cancer, Metabolic, Infectious Disease, Dental, Ophthalmic, Cardiovascular, and Other Clinical Indications. The Cancer segment is projected to expand at a CAGR of 7.5% during 2026 - 2034.
• By Functionality, the Europe Pharmaceutical Excipients Market is segmented into Coloring Agents and Coating Agents, Sweetner and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled Release, Antioxidant and Oil, Tablet Filler and Diluent, Binder and Compression and Granulating Agents, Emulsifiers, Surfactants, and Others. The Tablet Filler and Diluent segment is projected to expand at a CAGR of 6.4% during 2026 - 2034.
• By Surfactants For Functionality, the Europe Pharmaceutical Excipients Market is segmented into Polyoxyethylene Hydrogenated Castor Oil, Polysorbates, Sodium Dodecyl Sulfate, and Other Surfactants. The Polysorbates segment is projected to expand at a CAGR of 7.8% during 2026 - 2034.
• By Application, the Europe Pharmaceutical Excipients Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment is projected to expand at a CAGR of 6.9% during 2026 - 2034.
• By Oral For Application, the Europe Pharmaceutical Excipients Market is segmented into Tablet, Capsule, Liquid, and Others. The Tablet segment is projected to expand at a CAGR of 7.4% during 2026 - 2034.
• By Capsule For Oral, the Europe Pharmaceutical Excipients Market is segmented into Hard Gel and Soft Gel. The Hard Gel segment is projected to expand at a CAGR of 6.9% during 2026 - 2034.
• By End User, the Europe Pharmaceutical Excipients Market is segmented into Pharma Industries, Biopharma Industries, Animal Health, and Other End User. The Pharma Industries segment is projected to expand at a CAGR of 6.8% during 2026 - 2034.

By country, the Europe Pharmaceutical Excipients Market is categorized into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. The Rest of Europe is projected to expand at a CAGR of 5.8% during 2026 - 2034.

Key players operating in the Pharmaceutical Excipients Market are BASF SE, JRS PHARMA GmbH & Co KG, Roquette Freres SA, Avantor Inc, Archer-Daniels-Midland Co, Evonik Industries AG, Merck KGaA, The Dow Chemical Co, The Lubrizol Corp, Ashland Inc, and MEGGLE GmbH & Co KG, among others.

• In September 2025,  Evonik has launched MaxiPure Polysorbate 80 - a highly pure surfactant designed for injectable and biopharmaceutical applications. Engineered to meet the stringent demands of modern drug development, this ultra-high purity excipient addresses key challenges such as protein stability, viral inactivation, and the consistent solubilization of hydrophobic active pharmaceutical ingredients.
• In May 2025, Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announced the acquisition of IFF Pharma Solutions. This strategic milestone marks a significant step forward in its ambition to become a leader in support of the global pharma markets. With this acquisition, and following that of Qualicaps in 2023, Roquette decisively strengthens its position as a key player in the health industry by integrating IFF Pharma Solutions expertise and innovative product portfolio.